Sugi Predict

Sugi Predict / Compounds / SCHEMBL3736788

SCHEMBL3736788

SCHEMBL3736788

CC(C)[C@H](NC(=O)OCc1ccccc1)C(=O)OCCCC(=O)OC(C)(C)C

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ SYK P43405 1/20 0.50
▸ CTSK P43235 5/20 0.48
▸ CTSB P07858 4/20 0.48
▸ CTSL P07711 4/20 0.48
▸ CTSS P25774 3/20 0.48
▸ KLK5 Q9Y337 1/20 0.47
▸ MEN1 O00255 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ CASP1 P29466 1/20 0.46
▸ CASP3 P42574 1/20 0.46
▸ CASP7 P55210 1/20 0.46
▸ CASP6 P55212 1/20 0.46
▸ CASP8 Q14790 1/20 0.46
▸ CAPN1 P07384 1/20 0.46
▸ MAPT P10636 1/20 0.45
▸ ELANE P08246 1/20 0.44
▸ PRTN3 P24158 1/20 0.44
▸ CTSD P07339 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28870540 1.00 SYK (0.50) SYKCTSKCTSBCTSLCTSS
SCHEMBL24131771 0.97 SYK (0.49) SYKCTSKCTSBCTSLCTSS
SCHEMBL23748810 0.96 SYK (0.48) SYKCTSKCTSBCTSLCTSS
SCHEMBL23748811 0.96 SYK (0.48) SYKCTSKCTSBCTSLCTSS
SCHEMBL8125898 0.94 SYK (0.48) SYKCTSKCTSBCTSLCTSS
SCHEMBL3740512 0.91 KLK5 (0.52) SYKCTSKCTSBCTSLCTSS
SCHEMBL28870542 0.91 KLK5 (0.52) SYKCTSKCTSBCTSLCTSS
SCHEMBL23567826 0.90 CTSB (0.53) CTSKCTSBCTSLCTSSMEN1
SCHEMBL28870539 0.90 CTSB (0.53) CTSKCTSBCTSLCTSSMEN1
SCHEMBL25235990 0.88 KLK5 (0.51) SYKCTSKCTSBCTSLCTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240351975-A1 METHODS OF SYNTHESIZING 4-VALYLOXYBUTYRIC ACID XWPharma Ltd. (KY) 2024-10-24 — — US claimed
US-12612357-B2 Methods of synthesizing 4-valyloxybutyric acid XWPharma Ltd. (KY) 2026-04-28 — — US disclosed
US-20240351975-A1 METHODS OF SYNTHESIZING 4-VALYLOXYBUTYRIC ACID XWPharma Ltd. (KY) 2024-10-24 — — US disclosed
EP-4077262-B1 METHODS OF SYNTHESIZING 4-VALYLOXYBUTYRIC ACID XWPHARMA LTD (KY) 2024-07-24 — — EP disclosed
US-20230357130-A1 METHODS OF SYNTHESIZING 4-VALYLOXYBUTYRIC ACID XWPharma Ltd. (KY) 2023-11-09 — — US disclosed
US-11746081-B2 Methods of synthesizing 4-valyloxybutyric acid XWPharma Ltd. (KY) 2023-09-05 — — US disclosed
EP-4077262-A1 METHODS OF SYNTHESIZING 4-VALYLOXYBUTYRIC ACID XWPharma Ltd. (KY) 2022-10-26 — — EP disclosed
CN-115244028-A Synthetic method of 4-valyloxy butyric acid 凯瑞康宁生物工程有限公司 2022-10-25 — — CN disclosed
US-20220234994-A1 METHODS OF SYNTHESIZING 4-VALYLOXYBUTYRIC ACID XWPharma Ltd. (KY) 2022-07-28 — — US disclosed
US-11279669-B2 Methods of synthesizing 4-valyloxybutyric acid XWPharma Ltd. (KY) 2022-03-22 — — US disclosed
US-6974802-B2 Treatment of viral infections using prodrugs of 2′,3-dideoxy,3′-fluoroguanosine MEDIVIR AB (SE) 2005-12-13 — — US disclosed
US-20030186924-A1 Prodrugs MEDIVIR AB 2003-10-02 — — US disclosed
US-6458772-B1 Prodrugs MEDIVIR AB (SE) 2002-10-01 — — US disclosed
US-20020128301-A1 Non-nucleoside reverse transcriptase inhibitors AB, Medivir (SE) 2002-09-12 — — US disclosed
EP-1150956-A1 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MEDIVIR AB (SE) 2001-11-07 — — EP disclosed
EP-1121366-A1 PRODRUGS OF PHOSPHOROUS-CONTAINING PHARMACEUTICALS MEDIVIR AB (SE) 2001-08-08 — — EP disclosed
EP-1054891-A1 PRODRUGS MEDIVIR AB (SE) 2000-11-29 — — EP disclosed
WO-2000047561-A1 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MEDIVIR AB (SE) 2000-08-17 — — WO disclosed
WO-1999051613-A1 PRODRUGS OF PHOSPHOROUS-CONTAINING PHARMACEUTICALS MEDIVIR AB (SE) 1999-10-14 — — WO disclosed
WO-1999041275-A1 PRODRUGS MEDIVIR AB (SE) 1999-08-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240351975-A1 METHODS OF SYNTHESIZING 4-VALYLOXYBUTYRIC ACID GABBR1, GABBR2, GABRB3 SYK 4220/4885CTSK 4539/4885CTSB 2241/4885
US-12612357-B2 Methods of synthesizing 4-valyloxybutyric acid GABBR1, GABRB1, GABBR2 SYK 3872/4885CTSK 2875/4885CTSB 327/4885
US-20230357130-A1 METHODS OF SYNTHESIZING 4-VALYLOXYBUTYRIC ACID GABBR1, GABBR2, GABRB3 SYK 4220/4885CTSK 4539/4885CTSB 2241/4885
US-20030186924-A1 Prodrugs HAVCR2, CYP7A1, IGSF11 SYK 444/4885CTSK 2547/4885CTSB 1674/4885
US-11279669-B2 Methods of synthesizing 4-valyloxybutyric acid GABBR1, GABBR2, GABRB3 SYK 4220/4885CTSK 4539/4885CTSB 2241/4885
US-20220234994-A1 METHODS OF SYNTHESIZING 4-VALYLOXYBUTYRIC ACID GABBR1, GABBR2, GABRB3 SYK 4220/4885CTSK 4539/4885CTSB 2241/4885
US-11746081-B2 Methods of synthesizing 4-valyloxybutyric acid GABBR1, GABBR2, GABRB3 SYK 4220/4885CTSK 4539/4885CTSB 2241/4885
US-20020128301-A1 Non-nucleoside reverse transcriptase inhibitors SUB1, CBR1, GAR1 SYK 4776/4885CTSK 3753/4885CTSB 3486/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.